Berger & Montague is counsel to a proposed class of direct
purchasers of the anti-inflammatory drug Celebrex (celecoxib).
Berger & Montague is counsel in this class action
alleging that Pfizer committed fraud on the United States Patent
and Trademark Office and engaged in sham litigation to illegally
delay entry of generic celecoxib drugs into the market. As a
result of Pfizer's actions, plaintiffs paid more for celecoxib
products than they otherwise would have.
On November 6, 2015, the district court denied Pfizer's motion
to dismiss as to the fraud claim and granted the motion to dismiss
as to the sham litigation claim. Discovery is underway.
LEAD ATTORNEYS: David F. Sorensen, Ellen T. Noteware, Zachary D.